Wuhan Hvsen Biotechnology Co Ltd (300871) — Working Capital to Net Assets Ratio
Wuhan Hvsen Biotechnology Co Ltd (300871) has a Working Capital to Net Assets ratio of 31.8% as of March 2026. Working capital of CN¥721.05 Million (current assets of CN¥1.50 Billion minus current liabilities of CN¥777.87 Million) is measured against net assets of CN¥2.27 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Wuhan Hvsen Biotechnology Co Ltd (300871) financial flexibility to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Wuhan Hvsen Biotechnology Co Ltd Working Capital to Net Assets (2016–2025)
This chart shows how Wuhan Hvsen Biotechnology Co Ltd's Working Capital to Net Assets ratio has evolved across 10 annual periods from 2016 to 2025. As of March 2026, the ratio stands at 31.8%, reflecting working capital of CN¥721.05 Million against net assets of CN¥2.27 Billion CNY. See Wuhan Hvsen Biotechnology Co Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Wuhan Hvsen Biotechnology Co Ltd (2016–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Wuhan Hvsen Biotechnology Co Ltd from 2016 to 2025, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market cap of Wuhan Hvsen Biotechnology Co Ltd.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 25.9% | CN¥566.60 Million | CN¥2.19 Billion | CN¥1.31 Billion | CN¥740.33 Million | ▼ -0.7 pp |
| 2024 | 26.6% | CN¥389.27 Million | CN¥1.47 Billion | CN¥1.31 Billion | CN¥923.32 Million | ▼ -5.6 pp |
| 2023 | 32.1% | CN¥484.90 Million | CN¥1.51 Billion | CN¥1.27 Billion | CN¥781.08 Million | ▼ -3.3 pp |
| 2022 | 35.5% | CN¥546.55 Million | CN¥1.54 Billion | CN¥1.35 Billion | CN¥804.93 Million | ▼ -32.2 pp |
| 2021 | 67.7% | CN¥1.10 Billion | CN¥1.62 Billion | CN¥1.60 Billion | CN¥503.27 Million | ▲ +6.9 pp |
| 2020 | 60.8% | CN¥838.48 Million | CN¥1.38 Billion | CN¥1.18 Billion | CN¥338.67 Million | ▲ +37.3 pp |
| 2019 | 23.5% | CN¥88.78 Million | CN¥378.28 Million | CN¥292.54 Million | CN¥203.77 Million | ▼ -18.7 pp |
| 2018 | 42.2% | CN¥136.83 Million | CN¥324.52 Million | CN¥275.75 Million | CN¥138.92 Million | ▲ +15.4 pp |
| 2017 | 26.7% | CN¥59.62 Million | CN¥223.11 Million | CN¥177.70 Million | CN¥118.08 Million | ▲ +1.8 pp |
| 2016 | 24.9% | CN¥38.58 Million | CN¥154.70 Million | CN¥136.58 Million | CN¥98.00 Million | — |